Market News & Trends
Adare Pharmaceuticals Celebrates Corporate Headquarters Grand Opening
Adare Pharmaceuticals, a private global specialty pharmaceutical company, celebrated the official opening of its Corporate Headquarters located at 1200 Lenox Drive in Lawrenceville, New Jersey.…
"Engineering Medicines to Life" Campaign Highlights Capsugel's Unique Positioning as Specialty CDMO
After successfully completing four transformational acquisitions, as well as several other strategic investments, Capsugel today announced that it has unified them all under one brand…
Bristol-Myers Squibb & Nektar Therapeutics Announce Oncology Clinical Collaboration
Bristol-Myers Squibb Company and Nektar Therapeutics recently announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational medicine, NKTR-214, as a…
Abeona Therapeutics Announces Licensing of the AIM Next-Generation AAV Gene Therapy Vector Platform
Abeona Therapeutics Inc. recently announced the exclusive worldwide license of a next-generation gene therapy AAV capsid portfolio from University of North Carolina at Chapel Hill.…
Mucodel Pharma Announces Successful Completion of Buccal Naloxone Pilot Clinical Study
Mucodel Pharma LLC recently announced the successful completion of a pilot clinical study involving buccal naloxone (Exonal), a Mucodel product under development for the reversal…
Madrigal Pharmaceuticals & Tarveda Therapeutics Announce Exclusive License Agreement
Madrigal Pharmaceuticals, Inc. and Tarveda Therapeutics, Inc. recently announced an exclusive worldwide license agreement providing for the discovery, development, and commercialization by Tarveda of products…
ERT Recognized for Patient-Focused Technological Development in Clinical Trials
ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, recently announced it has been named a finalist for…
Caladrius Subsidiary, PCT, Announces 5-Year Strategic Manufacturing Services Agreement
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider (PCT, LLC, A Caladrius Company) with a select therapeutic development…
Allergan to Acquire Tobira Therapeutics, Expanding Global GI R&D Pipeline & Taking a Leading R&D Position in NASH
Allergan plc recently announced it has entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share,…
Australian Pharmaceutical Market to Surpass $25 Billion
Australia’s pharmaceutical market is set to rise from just over $22.85 billion in 2016 to $25.2 billion by 2020, registering a compound annual growth rate…
Virtual Pharma Companies: The Future is Now
Virtual Pharma Companies: The Future is Now Virtual pharma companies are growing because the business model works. Experience and flexibility is key…
Voyager Therapeutics & CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s Disease
Voyager Therapeutics, Inc. recently announced a research collaboration with CHDI Foundation, Inc. (CHDI) to advance Voyager’s VY-HTT01 program, an adeno-associated virus (AAV)-mediated gene-silencing therapy for…
Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement
Lonza Houston, Inc. and Massachusetts Eye and Ear have entered into a strategic agreement that provides customers the ability to in-license Anc80 and other Anc-AAVs…
Inovalon & MDLIVE Bring Real-Time Advanced Analytics to Telemedicine Marketplace
Inovalon recently announced a multi-year agreement with MDLIVE, a leading telehealth platform provider, to provide on-demand, real-time patient insights and analytics. The new capability will…
Geron Provides Update on Imetelstat Trials Being Conducted by Janssen
Geron Corporation recently provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews…
Dermira Acquires Option to License Exclusive Rights for up to Three Early Stage Programs from Takeda
Dermira, Inc. recently announced it has entered into an exclusive option and license agreement with Takeda Pharmaceutical Company Limited. Pursuant to the terms of the…
Catalent to Acquire Pharmatek, Adding Expanded Drug Development Services & Spray Drying Technology
Catalent, Inc. recently announced an agreement for Catalent, through its wholly owned subsidiary, Catalent Pharma Solutions, Inc., to acquire Pharmatek Laboratories, Inc., a West Coast,…
Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products
Amyris, Inc., the industrial bioscience company, recently announced that it has completed a subsequent collaboration agreement with Ginkgo Bioworks, which is expected to be approved…
Voyager Therapeutics Licenses Novel Gene Therapy Capsids From the California Institute of Technology
Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), recently announced a co-exclusive worldwide…
Epizyme Earns $6-Million Milestone Payment From GlaxoSmithKline
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, recently announced it has earned a $6 million milestone payment from GlaxoSmithKline (GSK). The milestone…
